SCHEMBL1750489

SCHEMBL1750489

O=C1c2ccccc2[N]c2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
CDC25B P30305 2/20 0.58
MAOA P21397 4/20 0.48
APAF1 O14727 3/20 0.48
KDM4E B2RXH2 2/20 0.48
LMNA P02545 2/20 0.48
MAPT P10636 2/20 0.48
GALK1 P51570 2/20 0.48
TDP2 O95551 2/20 0.48
NPC1 O15118 2/20 0.48
MAPK1 P28482 2/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
CES2 O00748 1/20 0.48
TERT O14746 1/20 0.48
PLIN1 O60240 1/20 0.48
S1PR4 O95977 1/20 0.48
PLA2G1B P04054 1/20 0.48
BCHE P06276 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1386281 0.84 MEN1 (0.46) MEN1KMT2ACDC25BMAOAAPAF1
SCHEMBL9709542 0.83 MAOA (0.62) MEN1KMT2ACDC25BMAOAAPAF1
SCHEMBL9709023 0.83 MAOA (0.62) MEN1KMT2ACDC25BMAOAAPAF1
SCHEMBL24062 0.82 MEN1 (0.37) MEN1KMT2ACDC25BMAOAAPAF1
SCHEMBL1749823 0.79 GAA (0.50) MEN1KMT2ACDC25BMAOAMAPT
SCHEMBL9709207 0.79 TDP2 (0.55) MEN1KMT2ACDC25BTDP2PTPRC
SCHEMBL7921203 0.78
SCHEMBL14157422 0.77 PTPRC (0.44) MEN1KMT2ACDC25BMAOAAPAF1
SCHEMBL3839654 0.75 MEN1 (0.42) MEN1KMT2ACDC25BMAOAAPAF1
Anthraquinone SCHEMBL1901249 0.75 MEN1 (1.00) MEN1KMT2ACDC25BMAOAAPAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0471516-A1 Tricyclic heterocyclic derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-02-19 EP claimed
US-9493420-B2 Quinoline derivatives and uses thereof PORTLAND STATE UNIVERSITY (US) 2016-11-15 US disclosed
US-8658648-B2 Modified chloroquines with single ring moiety or fused ring moiety DESIGNMEDIX, INC. (US) 2014-02-25 US disclosed
US-20130310348-A1 QUINOLINE DERIVATIVES AND USES THEREOF STATE UNIVERSITY (US) 2013-11-21 US disclosed
US-8524739-B2 Quinoline derivatives and uses thereof STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) 2013-09-03 US disclosed
EP-2379505-A1 MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY Designmedix, Inc. (US) 2011-10-26 EP disclosed
US-20110257160-A1 QUINOLINE DERIVATIVES AND USES THEREOF Board of Higher Education on behalf of Portland State University 2011-10-20 US disclosed
US-20110251210-A1 MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY PORTLAND STATE UNIVERSITY (US) 2011-10-13 US disclosed
US-7968539-B2 reversed chloroquines; to treat chloroquine resistant/sensitive malaria parasites; N'-(7-Chloro-quinolin-4-yl)-N-[3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-N-methyl-propane-1,3-diamine STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) 2011-06-28 US disclosed
WO-2010065932-A1 MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY DESIGNMEDIX, INC. (US) 2010-06-10 WO disclosed
EP-0471516-A1 Tricyclic heterocyclic derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-02-19 EP disclosed
US-4920103-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1990-04-24 US disclosed
US-4820694-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1989-04-11 US disclosed
US-4820695-A GRAMNEGATIVE BACTERIA ELI LILLY AND COMPANY (US) 1989-04-11 US disclosed
EP-0262903-A2 New acyl derivatives of 20-modified tylosin and desmycosin compounds ELI LILLY AND COMPANY (US) 1988-04-06 EP disclosed
EP-0262905-A2 Modifications of 3-0-demethyl-mycinose in macrocin and lactenocin ELI LILLY AND COMPANY (US) 1988-04-06 EP disclosed
EP-0262904-A2 Modifications of mycinose and 3-0-demethylmycinose in tylosintype macrolides ELI LILLY AND COMPANY (US) 1988-04-06 EP disclosed
US-4629786-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1986-12-16 US disclosed
EP-0103465-B1 20-AMINO MACROLIDE DERIVATIVES ELI LILLY AND COMPANY (US) 1986-09-10 EP disclosed
EP-0103465-A1 20-Amino macrolide derivatives ELI LILLY AND COMPANY (US) 1984-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251210-A1 MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY QARS1, MAVS, QDPR MEN1 3619/4885KMT2A 1757/4885CDC25B 1095/4885
US-20130310348-A1 QUINOLINE DERIVATIVES AND USES THEREOF RECQL, QARS1, QTRT1 MEN1 4170/4885KMT2A 1127/4885CDC25B 1330/4885
US-20110257160-A1 QUINOLINE DERIVATIVES AND USES THEREOF RECQL, QARS1, QTRT1 MEN1 4170/4885KMT2A 1127/4885CDC25B 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.